Despite a number of available treatments, insomnia is the most common medical complaint in general practice. It is the most common medical complaint in general practice affecting up to 30% of the adult population. Suvorexant, an orexin receptor antagonist (ORA), is the first in a new class of drugs in development for the treatment of insomnia. The current article highlights the potential role of this molecule for managing of insomnia .
Insomnia is characterized subjectively and may consist of a variety of complaints, including difficulty falling asleep, difficulty maintaining sleep, or experiencing nonrestorative sleep. A variety of treatment options is available for insomnia. The most common pharmacological interventions are benzodiazepines (BZDs) and the non-BZD gamma-amino-butyric acid (GABA)–acting hypnotics. Other less frequently prescribed agents include sedating antidepressants,…
